Use of oral antidiabetic drugs in Japanese working-age patients with type 2 diabetes mellitus: dosing pattern for metformin initiators
- 27 February 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Current Medical Research and Opinion
- Vol. 36 (5), 749-756
- https://doi.org/10.1080/03007995.2020.1729710
Abstract
Objective: To determine the pattern of antidiabetic drug use, with a particular focus on the metformin dose, among patients with type 2 diabetes mellitus (T2DM) in a Japanese working population. Methods: We used an administrative claims database linked to yearly health check-up data from large corporations. Data were collected for T2DM patients who began using an antidiabetic drug between 2014 and 2017 (n = 20,401). We evaluated the type of antidiabetic drug used and the characteristics of the patients using each type of drug. Among the metformin users, we assessed the titration in its dose or treatment during the 12-month period after initiation at 3-month intervals. Results: Among 20,401 new antidiabetic users, the most frequently used agents during the study period were dipeptidyl peptidase-4 inhibitors (DPP4i; 47.4%), followed by biguanides (18.5%) and sodium glucose cotransporter-2 inhibitors (SGLT2i; 6.7%). Most patients who initiated with metformin were prescribed 500 mg or less daily (72.9%); only 2.0% were prescribed a daily dose of >1000 mg. Moreover, 27% remained on the same daily dose during the 1-year follow-up, whereas another 29.9% discontinued their antidiabetic treatment altogether. Conclusions: A unique pattern of prescription was observed amongst Japanese patients with T2DM, and DPP4i, rather than metformin, was predominantly used as the first-line treatment. SGLT2i was infrequently prescribed. Metformin was prescribed at a daily dose of ≤500 mg in many patients. Greater efforts are needed to assess the comparative effectiveness of these treatment strategies.Keywords
This publication has 37 references indexed in Scilit:
- Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in Japan (JDDM32)Journal of Diabetes Investigation, 2013
- Efficacy, safety and dose–response relationship of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2013
- Japanese universal health coverage: evolution, achievements, and challengesThe Lancet, 2011
- How much do we spend on prescription medicines? Out-of-pocket costs for patients in Australia and other OECD countriesAustralian Health Review, 2011
- Efficacy and safety of metformin for treatment of type 2 diabetes in elderly Japanese patientsGeriatrics & Gerontology International, 2010
- Impact of Fixed-Dose Combination Drugs on Adherence to Prescription MedicationsJournal of General Internal Medicine, 2008
- Efficacy, dose–response relationship and safety of once‐daily extended‐release metformin (Glucophage® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double‐blind, placebo‐controlled studiesDiabetes, Obesity and Metabolism, 2004
- Efficacy of Metformin in Type II Diabetes: Results of a Double-Blind, Placebo-controlled, Dose-Response TrialThe American Journal of Medicine, 1997
- The assessment of refill compliance using pharmacy records: Methods, validity, and applicationsJournal of Clinical Epidemiology, 1997
- The Effects of High- and Medium-Dose Metformin Therapy on Cardiovascular Risk Factors in Patients With Type II DiabetesDiabetes Care, 1996